Status:
NOT_YET_RECRUITING
Application of Nanopore Adaptive Sequencing
Lead Sponsor:
Shenzhen Third People's Hospital
Conditions:
Liver Transplant Infection
Eligibility:
All Genders
Brief Summary
Infection post liver transplantation is an important factor in the death in patients. The traditional method of diagnosing infection post liver transplantation is laboratory tests. But the sensitivity...
Detailed Description
Based on the previous work, the investigators found that: 1. NAS has a higher microbial enrichment efficiency and can detect pathogenic information more quickly compared with nanopores normal sequenci...
Eligibility Criteria
Inclusion
- Accept liver transplantation
- Signing informed consent voluntarily
- Possessing ability to comprehend material information
- Participating this study voluntarily
Exclusion
- Participated another study
- Graft loss
- Have undergone a multi-organ transplantion or have had a previous organ transplantation
- Patient died
Key Trial Info
Start Date :
October 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06542042
Start Date
October 1 2024
End Date
October 30 2026
Last Update
August 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen Third People's Hospital
Shenzhen, Guangdong, China